Cargando…
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
BACKGROUND: Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being e...
Autores principales: | Sierra-Rodero, Belén, Cruz-Bermúdez, Alberto, Nadal, Ernest, Garitaonaindía, Yago, Insa, Amelia, Mosquera, Joaquín, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Laza-Briviesca, Raquel, Casarrubios, Marta, García-Grande, Aránzazu, Romero, Atocha, Franco, Fernando, Provencio, Mariano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395363/ https://www.ncbi.nlm.nih.gov/pubmed/34446577 http://dx.doi.org/10.1136/jitc-2021-002804 |
Ejemplares similares
-
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021) -
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022) -
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021) -
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022) -
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)